
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
almost 20 years ago
Case Studyalmost 20 years ago
Health Outcomes Beyond Glucose Controlalmost 20 years ago
Participating Facultyalmost 20 years ago
Introductionalmost 20 years ago
Oral Combination Therapy with Thiazolidinediones in Type 2 Diabetes





